• Explore /
  • Poster
  • / A phase 2 randomized study of oral docetaxel plus ritonavir (ModraDoc006/r) in patients with metastatic castration-resistant prostate cancer (mCRPC).

A phase 2 randomized study of oral docetaxel plus ritonavir (ModraDoc006/r) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

Ulka Vaishampayan

Ulka N. Vaishampayan

University of Michigan, Ann Arbor, MI

Ulka N. Vaishampayan , Marianne Keessen , Elisabeth I. Heath , Robert Dreicer , Tomas Buchler , Péter Ferenc Árkosy , Tibor Csoszi , Pawel J. Wiechno , Denis Kholtobin , Evgeny Kopyltsov , Neal D. Shore , Aleander Nosov , Sergey Orlov , Alexey Plekhanov , Maria Smagina , Sergey Varlamov , Nicholas J. Vogelzang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer– Advanced/Castrate-Resistant

Clinical Trial Registration Number

NCT04028388

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 5016)

DOI

10.1200/JCO.2022.40.16_suppl.5016

Abstract #

5016

Poster Bd #

200

Abstract Disclosures

Similar Posters

First Author: Jorge A. Garcia

First Author: Sumit Kumar Subudhi

First Author: Daniel Peter Petrylak

First Author: Vincenza Conteduca